There are several anti-TNF therapies on the market for the treatment of rheumatoid arthritis, which include AbbVie’s anti-TNF Humira (adalimumab).
GlobalData’s annual forecast predicts Ojjaara’s global sales to reach $575m in 2031.
GlobalData forecasts that the drug will be one of the most successful in the obesity market by 2031.
Eli Lilly witnessed the largest growth in market capitalisation of 36.1% over Q2 2023, propelling the company to the top of the list.
Currently, NSCLC patients with EGFR exon 19 deletions or L858R substitution face limited therapeutic options after seeing disease progression post-front-line treatment.
Give your business an edge with our leading industry insights.
According to GlobalData’s analyst consensus forecasts, GlobalData anticipates Reblozyl’s projected total annual sales to reach $3.2bn by 2029.
Mounjaro as a therapy for T2D is likely to gain significant uptake in the primary care space, as well as eventually in specialist weight loss management services.
RSV, a common infectious disease of the lungs and respiratory tract, can cause further health problems such as bronchiolitis and pneumonia.
Direct oral anticoagulant (DOAC) use may not be approved in VTE cancer patients, but GlobalData KOLs share that these drugs are becoming commonplace as a treatment.
Dr Baigini noted that most of the guidelines are new, rather than an update on existing guidelines, with the exception of the section on hypertrophic cardiomyopathy (HCM).